Effect of a peptide construct on differentiated macrophage MMP-2 and MMP-9 levels of varicose patients.
The matrix metalloproteinase (MMPs) secreted from macrophages can affect the extracellular matrix remodeling process and develop the varicose. The aim of this study was to investigate the MMP-2 and MMP-9 gene expression levels and gelatinolytic activities in the macrophages differentiated from monocytes of varicose patients and to evaluate a peptide construct on their activities. The macrophages were differentiated from the monocytes of varicose patients using M-CSF. The MMP-2 and MMP-9 expression levels and activities were measured by RT-qPCR and Zymography techniques. A peptide construct (ESLCG) was predicted with bioinformatics tools and was the subjects for the study of inhibitory effects as compared to Batimastat. Furthermore, the docking studies were performed for the peptide construct and Batimastat. The results showed the significant increases in MMP2 and MMP9 gene expression levels (P<0.001 and P<0.004, respectively) and gelatinolytic activities (P<0.001 and P<0.0001, respectively) in the macrophages. In agreement with the inhibitory effects of Batimastat, the peptide construct inhibit the MMP-2 and MMP-9 gelatinolytic activities up to 20% and 12 % in concentration of 125 µM. The docking analyses showed that the Lys187, Arg98, Leu49, Gly189, Leu190, Met97, Tyr53 and Phe57 residues of MMP-2 and the Leu187, His190, Glu402, His401, His405 and His411 residues of MMP-9 are involved with both Batimastat and ESLCG peptide. The ESLCG peptide may be applied as an inhibitory factor for the increased MMP-2 and MMP-9 activities in varicose disease.